D L Carlson Investment Group Inc. Buys New Position in Stryker Corporation $SYK

D L Carlson Investment Group Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,810 shares of the medical technology company’s stock, valued at approximately $3,089,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter valued at about $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter worth approximately $27,000. Finally, Gables Capital Management Inc. acquired a new stake in Stryker during the second quarter valued at approximately $25,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Stryker stock opened at $327.97 on Friday. The firm’s 50 day simple moving average is $326.64 and its 200-day simple moving average is $332.66. The company has a market cap of $125.80 billion, a P/E ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SYK. Leerink Partners reduced their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. JPMorgan Chase & Co. dropped their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Barclays cut their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Citigroup reissued a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Finally, Raymond James Financial set a $370.00 target price on Stryker in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In other news, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 665,370 shares of company stock worth $216,238,501 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.